Related Experiment Video

Updated: May 10, 2025

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

5.8K

Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology

Yingying Duan1,2, Zhaoshuo Liu1,2, Qilin Wang1,2

  • 1School of Engineering Medicine, Beihang University, Beijing 100191, China.

Genes & Diseases
|April 28, 2025
PubMed

Insights

MYC is a key driver in most cancers, regulating critical cell functions. This review explores direct and indirect therapeutic strategies to target MYC for effective cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • MYC dysregulation is implicated in ~70% of human cancers.
  • MYC controls essential biological processes including cell cycle, metabolism, apoptosis, and immune escape.
  • MYC is a central regulator of carcinogenesis, tumor development, and drug resistance.

Purpose of the Study:

  • To review the multifaceted roles of MYC in cancer progression.
  • To highlight therapeutic strategies targeting MYC in cancer therapy.
  • To discuss direct and indirect approaches for MYC inhibition.

Main Methods:

  • Literature review of MYC's role in cancer.
  • Analysis of direct MYC targeting strategies (e.g., MYC-MAX complex).
  • Exploration of indirect MYC targeting approaches (transcriptional/translational inhibition, protein destabilization, synthetic lethality).

Main Results:

  • MYC's extensive involvement in cancer pathogenesis is confirmed.
  • Direct targeting of MYC, while challenging, is feasible via complexes like MYC-MAX.
  • Indirect strategies offer pragmatic therapeutic avenues for MYC-driven cancers.

Conclusions:

  • MYC is a critical and druggable target in oncology.
  • A range of therapeutic strategies, both direct and indirect, are being developed to combat MYC-driven cancers.
  • Targeting MYC holds significant promise for future cancer therapies.
Keywords:
MYCMYC inhibitorsMYC-Regulated biological processesOncogenic deregulationTherapeutic strategies

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.8K